Table 3.

Potentially complement activating autoantibodies relevant in differential diagnosis of hepatobiliary disorder.

Assay	AIH	PBC	Viral Hepatitis
Transaminases (AST, ALT)	++	(+)a	+
Cholestasis (AP, GGT) Bilirubin, Lipids	+++	++	(+)
IgG	++	(+)b	+
IgM	(+)c	++	–
ANA IIF	+(- for AIH type 2)	+	(+)d
ANA IIF different patterns, e.g. ICAP – AC nomenclaturee	+	e.g.AC-3/6/11/12	(+)d
ANA IIF pattern ICAP AC-6 nuclear dots		++f
ANA IIF pattern ICAP, AC-11/AC-12, nuclear membrane		++g
ANA IIF pattern ICAP AC-3 centromer		++h
AMA	(+)i	++j
Anti-M2	–	++k
Anti-SMA/actin	++l	(+) some cases	(+)l
Anti-LKM-1l	++m	–
Anti-SLA/LP	++n	–
Anti-LC1o	++ (for AIH type 2)	–
Anti-C4b/C3c	ND	ND	++

^aoverlaps with AIH.

^boverlaps with AIH.

^coverlaps with PBC.

^dnon-reactve for AIH-2/unspecifically present in case of infectious, e.g. HEV or toxic processes.

^esee: www.anapatterns.org.

^fconfirmation by ELISA advised; antigen: sp100.

^gconfirmation by ELISA advised; antigen gp210.

^hconfirmation by ELISA; centromer.

ⁱoverlaps ith PBC.

^jEscherica coli infection induces AMA, often unspecifically present [89].

^kserologimarker for PBC: anti-mitochondrial type 2, confirmation marker.

^lAIH-type: confirmation by blot, IIF on VSM47 cell line; when acute hepatitis E: often unspecifically present (90).

^mAIH-type: confirmation by ELISA; blot on cytochrom p450 2 D6, possible also with HCV infection CAVE: diagnostic error.

ⁿAIH-1 type 1: serologic marker for AIH-1 (earlier for AIH-3): only ELISA, blot available.

^oAIH-type 2: in IIF overlap by LKM also isolated; confirm with ELISA.